NSE: VIYASH | BSE: 512529

Mid-range Performer

Download real time

226.00 0.07 (0.03%)

26.87% Gain from 52W Low

2.3M NSE+BSE Volume

NSE 16 Oct, 2026 3:31 PM (IST)

9,983.9

Market Cap

High in industry

Beta 1Year

Very High Volatility

Viyash Scientific Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for VIYASH, BSE:512529 Viyash Scientific Ltd.

Search Inside the pdf :

Viyash Scientific Ltd.

25 Mar 2026

226.00

0.03%

VIYASH SCIENTIFIC LTD.

Buy: Viyash Scientific Ltd.

Target

Joindre Capital Services

Transformational Merger: Creation of a vertically integrated Human + Animal Health platform eliminates internal inefficiencies and builds full value-chain control from intermediates to formulations. Scale & Global Footprint Expansion: Post-merger entity operates 16 manufacturing facilities serving 150+ countries. Strong presence across regulated markets enhances credibility and growth visibility. API & CDMO Entry Boost: Viyash adds strong backend capabilities with USFDA plants and 200+ scientists. Positions the company to benefit from outsourcing...

Promoters have decreased holdings from 61.31% to 49.24% in Sep 2026 qtr

Viyash Scientific Ltd.

05 Jul 2023

226.00

0.03%

Sequent Scientific Ltd | Company Note

Not Rated: Viyash Scientific Ltd.

Edelweiss

A turnaround story

Viyash Scientific Ltd. has an average target of 258.00 from 1 broker.

Viyash Scientific Ltd.

27 May 2022

226.00

0.03%

BP Equities Sequent Scientific Ltd. Q4FY22 Result Update1

Buy: Viyash Scientific Ltd.

Target

BP Wealth

Viyash Scientific Ltd. is trading below all available SMAs

Viyash Scientific Ltd.

14 Feb 2022

226.00

0.03%

BP Equities Sequent Scientific Ltd. Q3FY22 Result Update

Buy: Viyash Scientific Ltd.

Recommendation Target

BP Wealth

Sequent Scientific (SSL) has posted revenue of INR 3,580mn with a 0.8% YoY increase, which was 14.6% above our estimate of INR 3,124mn. The revenue beat was mainly driven by higher than expected growth in formulation business (mainly in Turkey); However, API business de-grew by 20.1% (YoY) due to lower offtake of Albendazole (key product in API). Moreover, Logistical challenges (port congestion, vessel availability) has also impacted API sales in Q3. The formulation business grew by 18.5% (YoY), led by strong performance in LATAM (+52.6% YoY) and Turkey (+34.2%) on a constant currency basis. India business performed well across both Cattle & Poultry segments with a growth of 20.5% (YoY). Revenue from Emerging markets (ex India) declined by 3.4%. Management expects a strong recovery in the API business during Q4 supported by a strong order book and revival in...

Promoters have decreased holdings from 61.31% to 49.24% in Sep 2026 qtr

Viyash Scientific Ltd.

03 Nov 2021

226.00

0.03%

BP Equities Sequent Scientific Ltd. Q2FY22 Result Update

Hold: Viyash Scientific Ltd.

Target

BP Wealth

Sequent Scientific (SSL) has posted revenue of INR 3,506mn with a 1.2% YoY increase, which was 13% above our estimate of INR 3,102mn. The revenue beat was mainly driven by higher than expected growth in formulation business; However, API business de-grew by 10.4% (YoY) due to lower offtake of Albendazole (key product in API). The formulation business grew by 6.1% (YoY), led by strong performance in LATAM (+34.5% YoY) and Europe (+10.3%). India business growth moderated (+4.2%) due to the base effect of Zoetis commercialization in Q2FY21. Currency depreciation overshadows double-digit growth in Turkey business (de-grew by 6.6% YoY). Revenue from Emerging markets declined by 23.4%. Management expects a strong recovery in the API business during the second half of the year. EBITDA margin witnessed a sharp contraction of 1067bps to 5.6% level (lowest in last four years), which was 632bps lower than our estimate due to negative operating leverage in API business and higher employee cost (due to ESOP). Despite income tax credit (tax rate 250% vs 20.7% in Q2FY21), reported PAT came at INR 143mn (-52.8% YoY) compared to our expectation of INR.159mn due to operationally weak performance. Management maintained revenue...

Promoters have decreased holdings from 61.31% to 49.24% in Sep 2026 qtr

Viyash Scientific Ltd.

05 Feb 2021

226.00

0.03%

BP Equities Sequent Scientific Ltd. Q3FY21 Result Update

Hold: Viyash Scientific Ltd.

Recommendation Target

BP Wealth

to 18.5% level, which was 111bps higher than our estimate driven by positive operating leverage. SSL Key Data reported a PAT of INR 372mn compared to our estimate of INR 302mn (23% above our estimate) led by operationally strong performance. Management maintained its revenue growth guidance of the mid -teen level. However, trimmed down margin growth guidance to 100bps (from earlier 200bps) YoY for the medium term due to remain competitive in the challenging pricing environment. The company...

Viyash Scientific Ltd. is trading below all available SMAs

Viyash Scientific Ltd.

09 Nov 2020

226.00

0.03%

BP Equities Sequent Scientific Ltd. Q2FY21 Result Update

Buy: Viyash Scientific Ltd.

BP Wealth

driven by positive operating leverage. During the quarter the company incurred one-time expenses of BSE code INR 90mn (onetime bonus and ESOPs of INR 52.1mn and INR 38.3mn related to discontinuation of Alivira France operations) under Exceptional item. SSL reported a PAT of INR 213mn compared to our estimate of INR 250mn. Adjusting onetime expenses, the Normalised PAT came in at INR297mn...

Viyash Scientific Ltd. has an average target of 258.00 from 1 broker.

Viyash Scientific Ltd.

22 Sep 2020

226.00

0.03%

BP Equities Sequent Scientific Ltd. Initiating Coverage BUY Trgt 224

Buy: Viyash Scientific Ltd.

BP Wealth

Promoters have decreased holdings from 61.31% to 49.24% in Sep 2026 qtr

Viyash Scientific Ltd.

15 Apr 2019

226.00

0.03%

SEQUENT SCIENTIFIC LIMITED

Buy: Viyash Scientific Ltd.

Joindre Capital Services

Incorporated in 1985, SeQuent Scientific Ltd (SSL) undertakes its animal health business via Alivira Animal Health Limited, which is engaged in manufacturing veterinary APIs and formulations. Earlier SSL was engaged in the manufacturing human APIs, which has been demerged with effect from October, 2017. SSL is now involved in manufacturing Praziquantel a human and animal API and intermediates. SSLs subsidiary - SeQuent Research Limited - offers analytical services to the pharma industry. SSLs (consolidated) portfolio consists of about 23 commercial products in animal health API and over 500 products across 12...

Viyash Scientific Ltd. is trading below all available SMAs

Is Sequent Scientific Ltd. worth buying?

329 Votes:

Buy 82.37%

Sell 10.64%

Hold 6.99%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Not Rated SEE REPORTS >

pdf link